| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ORIGINAL ARTICLE |
expression increases with increasing Gleason score and with hormone insensitivity in prostate carcinoma
1 Histopathology Department, John Radcliffe Hospital, Headington, Oxford, UK
2 Department of Pathology, Adelaide and Meath Hospital Incorporating the National Children’s Hospital, and Trinity College, Dublin, Ireland
3 Department of Pathology, Coombe Women’s Hospital, and Trinity College Dublin
4 Department of Pathology, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin
Correspondence to:
Dr C Hughes
Histopathology Department, John Radcliffe Hospital, Headington, Oxford OX3 9DZ, UK; caroline.hughes{at}orh.nhs.uk
Aim: To investigate and compare topoisomerase II-
expression in benign prostatic hyperplasia (BPH), prostate cancer of varying Gleason scores and hormone-insensitive prostate cancer.
Methods: The immunohistochemical expression of topoisomerase II- antibody in the above-mentioned diagnostic categories was investigated and compared.
Results: Increased expression of topoisomerase II- was seen in the prostate cancers of Gleason scores 7 and 8–10 (p = 0.000) compared with prostate cancers of Gleason score 6 and BPH (p = 0.245). Statistically significant differences were found in the topoisomerase II- gene expression between prostate cancers categorised by Gleason Score. Also, increased expression of topoisomerase II- was seen in the known hormone-resistant prostate carcinomas compared with prostate cancers with no hormone treatment in the subgroup with Gleason scores 8–10, which approached statistical significance (p = 0.081). No statistically significant difference was observed in topoisomerase II- expression between the groups with BPH and prostate carcinoma of Gleason score 6 (p = 0.245).
Conclusion: Topoisomerase II- expression was found to increase with the known prognostic marker Gleason score and with hormone insensitivity. Objective evidence is provided for clinical trials with drugs targeting topoisomerase II- to be targeted to patients with prostate cancers of Gleason Score >6 and, in particular, prostate cancers of Gleason Scores 8–10.
Abbreviations: BPH, benign prostatic hyperplasia
This article has been cited by other articles:
|
|
 |
|
  J. C. Cheville, R. J. Karnes, T. M. Therneau, F. Kosari, J.-M. Munz, L. Tillmans, E. Basal, L. J. Rangel, E. Bergstralh, I. V. Kovtun, et al. Gene Panel Model Predictive of Outcome in Men at High-Risk of Systemic Progression and Death From Prostate Cancer After Radical Retropubic Prostatectomy J. Clin. Oncol., August 20, 2008; 26(24): 3930 - 3936. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Kosari, J. M. A. Munz, C. D. Savci-Heijink, C. Spiro, E. W. Klee, D. M. Kube, L. Tillmans, J. Slezak, R. J. Karnes, J. C. Cheville, et al. Identification of Prognostic Biomarkers for Prostate Cancer Clin. Cancer Res., March 15, 2008; 14(6): 1734 - 1743. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Pourpak, T. H. Landowski, and R. T. Dorr Ethonafide-Induced Cytotoxicity Is Mediated by Topoisomerase II Inhibition in Prostate Cancer Cells J. Pharmacol. Exp. Ther., June 1, 2007; 321(3): 1109 - 1117. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Murphy, C. A. Hughes, C. Barrett, H. Magee, B. Loftus, J. J. O'Leary, and O. Sheils Low-Level TOP2A Amplification in Prostate Cancer Is Associated with HER2 Duplication, Androgen Resistance, and Decreased Survival Cancer Res., March 15, 2007; 67(6): 2893 - 2898. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
| Journal of Clinical Pathology | Molecular Pathology |
